A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. (Q48052209)
Jump to navigation
Jump to search
scientific article published on 20 January 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. |
scientific article published on 20 January 2015 |
Statements
1 reference
A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. (English)
1 reference
Manfred Westphal
Oliver Heese
Joachim P Steinbach
Oliver Schnell
Gabriele Schackert
Maximilian Mehdorn
Dirk Schulz
Matthias Simon
Uwe Schlegel
Karsten Geletneky
Christian Braun
Joachim G Hartung
Dirk Reuter
Monika Warmuth Metz
Ferdinand Bach
20 January 2015
1 reference